INTRODUCTION
Glucocorticoid excess results in osteopenia. This detrimental action of glucocorticoids on bone is probably mediated both directly at the level of the bone as well as indirectly by inhibition of Ca++ absorption from the gastrointestinal tract. We have previously demonstrated the presence of glucocorticoid receptors in bone cells (1, 2) , and we, and others, have shown that glucocorticoids exert a direct inhibitory action on bone cell function (2) (3) (4) . However, all of these studies were performed on mixed populations of bone cells. Recently, Wong and Cohn (5) and Peck et al. (6) have developed techniques to separate rodent bone cells into distinct populations possessing properties characteristic of osteoblasts and osteoclasts. We felt it would be of great interest to determine which of these populations possessed glucocorticoid receptors and, if both cell types were glucocorticoid targets, to ascertain whether glucocorticoids elicited different actions in each cell type. Moreover, we have recently demonstrated that glucocorticoid treatment potentiates the ability of parathyroid hormone (PTH)1 to stimulate cyclic AMP (cAMP) generation in mixed bone cells (7) . Employing separated bone cells would allow us to differentiate whether PTH was enhancing 1Abbreviations used in this paper: BSA, bovine serum cAMP in osteoblast, osteoclast, or both populations, as well as to compare the glucorticoid effect on PTHstimulated cAMP with that of calcitonin (CT). By identifying the separate actions of glucocorticoids on the two major bone cell tvpes, it was hoped that these studies would shed further light on the mechanism,s by which glucocorticoid excess leads to osteopenia.
METHODS
Culture of different populationis of bone cells. Bone cells from 20-d-old fetal rat calvaria were dispersed by collagenase digestion and cultured as previously described (2) except for the use of autoclavable minimum essential medium with Earle's salts (F-17, Grand Island Biological Co., Grand Isand, N. Y.) instead of filtered minimum essential medium (F-11). The growth pattern, biochemical response, and morphology of the cells cultured in these two media were essentially the same. To separate bone cells into different subpopulations, two techniques were used; (a) the method of Peck et al. (6) employed mechanical scraping of periosteal and endosteal tissues to obtain osteoclasts, leaving residual osteoblasts to be digested with collagenase, and (b) the method of Wong and Cohn (5) employed timed, sequential, enzymatic digestion with collagenase. In some early experiments, both methods were used. In both cases, the collagenase incubation was performed at 37°C with 2 mg/ml of enzyme (CLS II, Worthington Biochemical Corp., Freehold, N. J.) in a gyratory water bath shaker at 175 rpm/min. In later experiments, only enzymatic digestion was employed. The populations designated "OC" (indicating osteoclast-like) were released during the first 30 min of collagenase digestion, and the populations designated "OB" (indicating osteoblast-like) were released during the following 90 min of digestion; that is, between 30 and 120 min. Cells were cultured separately for 6-7 d, at which time both populations reached confluency.
Except for the cell growth studies, dexamethasone treatments were generally made 2 d before termination ofthe experiment.
Dexamethasonie added to the culture near confluency did not change the cell number.
Hormonal stimulation ofcAMP generation. On the day of the experiment, cells in 6-oz glass bottles, pretreated with vehicle (0.05%) or dexamethasone, were incubated in serumfree medium containing 1 mg/ml bovine serum albumin (BSA), 25 mM Hepes, and 0.01 mM of isobutylmethyl xanthine (Aldrich Chemical Co., Inc., Milwaukee, Wis.) for 10 min. Synthetic bovine PTH (PTH 1-34 peptide, 3, 820 IU/mg, Beckmiiani Instruments Inc., Spinco Div., Palo Alto, Calif.) or synthetic salmon CT (4,700 Medical Research Council U/mg, a gift from Dr. James Bastian, Armour Pharmaceutical Co., Chicago, Ill.) was added for 2 min. The period of hormonal stimulation was terminated by removal of the medium, washing with Dulbecco's Ca`+-Mg++-free phosphate-buffered saline, and immediate addition of absolute ethanol. In doseresponse studies (as illustrated by Fig. 4) , to conserve hormones, cells were scraped from large culture bottles and suspended in 1 ml of BSA medium in 1.5-ml plastic centrifuge tubes to which PTH or CT was added. The reaction was terminated by a 30-s centrifugation in a microfuge (Model B, Beckman-Instruments, Inc., Spinco Div.), removal of the medium, and the addition of ethanol. The amount of cAMP extracted by ethanol was assayed by the protein-binding method of Gilman (8) with modifications as previously described (7).
Glucocorticoid receptor binding assay. After 7 d in culture, monolayers in liter-size glass bottles were digested with collagenase solution (1 mg/ml collagenase, 1 mg/ml glucose in phosphate-buffered saline) to remove extracellular matrix. The cells were then lysed with a Dounce homogenizer (Kontes Co., Vineland, N. J.) in hypotonic buffer A (10 mM Tris, 0.1 mM EDTA, 1 mM thioglycerol). Cytosol was prepared and binding was performed at 0°C for 4 h. Free [3H]dexamethasone was removed by charcoal adsorption. One-tenth the incubation volume of charcoaldextran mixture (0.5 mg of Norit A [American Norit Co., Jacksonville, Fla.] plus 0.05 mg Dextran T70 [Pharmacia Fine Chemicals Inc., Piscataway, N. J.] per milliliter) was added to the [3H]dexamethasone-labeled cytosol and, after 20 min incubation at 0°C, the charcoal-dextran pellet was removed by centrifugation (2,000 g for 10 min), and an aliquot of supernate was radioassayed for bound [3H]dexamethasone. Another aliquot from the supernate was taken for protein determination by the method of Bradford (9) .
Cell growth and alkaline phosphate assay. Cells were grown in 1.6-cm diameter plastic multiwelled dishes (Linbro Chemical Company, Hamden, Conn.). In cell growth experiments, cultures were changed to medium containing varying concentrations of dexamethasone on the 2nd day of culture and continued for four days. They were removed from the wells after incubation with collagenase solution at 37°C for 1 h. Aliquots of the dispersed cells were counted electronically (Coulter Counter, Coulter Electronics Inc., Hialeah, Fla.) to determine cell numbers, or DNA was determined by the method of Burton (10) .
To assay alkaline phosphatase activity, cells were treated with dexamethasone for the final 2 d in culture and assayed on the 7th day. Monolayers were digested with collagenase as in growth experiments, and the dispersed cells were washed thoroughly with phosphate-buffered saline and sonicated in 0.5 ml of cold buffer containing 10 mM Tris and 0.1% sodium deoxycholate (pH 7.4). Aliquots of the sonicate were assayed for phosphatase activity at pH 10.1 by the method ofLowry (11) with 4 mM of p-nitrophenyl phosphate (Sigma Chemical Co., St. Louis, Mo.) as substrate.
Adenylate cyclase assay. Cells pretreated with or without dexamethasone in liter-size bottles were dispersed by collagenase, and the washed cells were disrupted in hypotonic buffer B (10 mM Tris, 1 mM EDTA, 1 mM dithiothreitol) with a Dounce homogenizer. Then, a volume of 2 M sucrose was added to bring the sucrose concentration to 0.25 M. The homogenate was centrifuged at 200g for 10 min, and the supernate was removed and recentrifuged at 30,000g for 10 min. The upper white-colored fraction of the pellet was gently removed by aspiration with a Pasteur pipet. This membrane fraction was resuspended by gentle homogenization in the same buffer containing 0.25 M of sucrose. Aliquots of the membrane suspension containing 25-50 ,ug of protein were used for the assay. Adenylate cyclase activity was measured by a modification of the method described by Marcus and Orner (12) . An aliquot of the membrane fraction was added to the reaction mixture to initiate the reaction.
The final reaction mixture contained in a 100-,ul vol: 50 mM of Tris buffer (pH 7.4), 0.5 mM of MgCl2, 30 mM KCl, 0.015% BSA, 0.5 mM isobutylmethyl xanthine, 1 mM ATP, 4 mM creatine phosphate, 20 ,ug creatine phosphokinase, and PTH, guanylyl imidodiphosphate (G,p[NH]p), or NaF as indicated.
Incubations were performed at 30°C for 15 min and terminated by the addition of 100 ,l of 25 mM EDTA in 0.05 M sodium acetate and acetic acid buffer (pH 6.2) followed by boiling for 3 min. The boiled mixture was centrifuged for 10 min at 2,000 g, and aliquots of supernate were assayed for cAMP by radioimmunoassay. Phosphodiesterase assay. Cells cultured in 6-oz bottles, pretreated for 2 d with vehicle of varying amounts of dexamthasone, were used in these experiments. Cells were homogenized in cold, 0.25-M sucrose after removal from the bottles and washing with phosphate-buffered saline. cAMP phosphodiesterase activity of the homogenate was measured by the method of Marcus (14) with minor modifications as described earlier (7). DNA was extracted from the 2,000 g pellet with 10% perchoric acid and assayed by the method of Burton (10) .
RESULTS
Differentially enriched bone-cell populations. The possibility of obtaining subpopulations of bone cells differentially enriched for OB and OC cells was pursued with a combination of the methods described by Wong and Cohn (5) Dexamethasone effects on cell growth. We previously found that glucocorticoid addition to bone cell cultures had an antiproliferative action when the steroids were added in the early phases of the culture period (2). These findings are expanded in the present study and, as shown in Table I Dexamethasone regulation of alkaline phosphatase activity. Dexamethasone treatment of cultured cells early in the culture period, when cell numbers were inhibited by steroid exposure, failed to alter alkaline phosphatase activity (2) . However, dexamethasone addition to cultures when DNA values were unaltered did lead to inhibition of alkaline phosphatase activity (Table II) . The basal level of alkaline phosphatase activity is very high in OB cells; OC cells possessed about one-sixth the activity. Both populationis showed a similar dose-dependlent inhibition of enzyme activity in response to dexamethasone addition late in the culture period.
Dexamethasone modulation of PTH and CT stimulation of cAMP generation. We previously showed that dexamethasone potentiated the ability of PTH to stimulate cAMP in mixed bone cells (7) . In the present study, we examined the effects of dexamethasoine separately on OB and OC cells and for both PTH and CT stimulation. Fig. 1 illustrates the results of treating bone cells with 13 nM dexamethasone for the last 2 d in culture. This concentration of dexamiiethasonie is slightly below the dose which achieves saturationi of the receptor sites. The cells were then exposed to either PTH or CT for 2 min, and cAMP was measured. Pilot experiments determined that this was the timiie of peak cAMP generationi (7). Dexamiiethasonie treatment did not measurably alter basal levels of cAM\1P in either OB or OC cells. The ability of PTH to stimulate cAMP was greatly potentiated by glucocorticoid treatment in OB cells. A siimilar effect was present but much less marked in OC cells. CT did not stimulate cAMP production in OB cells in the presence or absence of dexamethasone (Fig. 1) . Although CT did stimulate cAMP in OC cells, the CT effect was not potentiated by dexamethasone treatmiienit.
Glucocorticoid potentiation of PTH-stimulated cAMP generation could be the result of dexamethasoine- Significantly different from -Gpp(NH)p treatmenit at P < 0.001.
DISCUSSION
This study confirms the findings of other workers (5, 6) that bone cells obtained from neonatal rodeint calvaria can be resolved into separate populations enriched for OB and OC cells (Table I , Fig. 1 ). The enrichment method is based on the anatomical localization of the cells in calvaria: OC at the surface and OB in a deeper location. The OB population appears to be predominantly made up of osteoblasts. The cells contain high levels of alkaline phosphatase and respond primarily to PTH stimulation (Fig. 1 , Table II ); in contrast, the OC population responds both to PTH and CT (Fig. 1) . The OC population problab)ly represents a heterogenous collection of cells, some of which are osteoclasts or at least CT-responsive, and some of which max' be osteoblasts or osteocvtes. The rise A possibility requiring considerationi is that the rise in cAMP in OC cells after PTH stimulation is totally a result of contamination by OB cells. However, the m-agnitude of the cAMP response and the amount of contamination estimated by alkaline phosphatase activity does not support this hypothesis. The cAMP generated at any given dose of PTH in OC cells is -50% that of OB cells (Figs. 1 and 4) . However, the maximal overlap of OB cells into the OC population is approximately one-sixth, assuming that OC cells do not possess any alkaline phosphatase activity at all (Table II) . We conclude that some non-OB cells in the OC population respond to PTH stimulation. However, a recent report by Goldring et al. (19) indicates that the cAMP response to PTH miay be more widespread thain previously considered.
Both cell populations were found( to possess glucocorticoid receptors (Fig. 2) , which suggests that both cell types are glucocorticoid targets. In spite of other biochemical differences between the GB and OC cells, 1)oth populations possessedl the saimie concentration of glucocorticoid receptors (Fig. 2) , and the properties of the receptor appeared to be identical in the two cell types resembling glucocorticoid receptors described in other target tissues (20) Functional studies indicated that glucocorticoid treatment was inhibitory to both populations. When administered early in the culture period, dexamethasone elicited dose-dependent inhibition of OB and OC cell growth (Table I) . Alkaline phosphatase activity was inhibited in both populations, even at times in the culture period when dexamethasone failed to exhibit its antiproliferative action (Table II) . The two populations appear equally responisive to glucocorticoid as evidenced by an equivalent degree of inhibition.
We have previously shown that glucocorticoids potentiate PTH stimulation of cAMP production in mixed bone cell cultures (7) . In the present study, we examined the ability of glucocorticoid to alter the cAMP response of separated OB and OC cells to PTH and CT. The findings were that dexamethasone did significantly potentiate the cAMP response to PTH in OC cells as well as OB cells (Figs. 1 and 4) . The mechanism by which glucocorticoids potentiate the cAMP response was next examined. We previously reported an inhibition of phosphodiesterase by dexamethasone in a mixed population of bone cells (7) . The present data show an equivalent glucocorticoid inhibition of phosphodiesterase activity in both populations. Because of the differences in cAMP potentiation in OB and OC cells (Fig. 1) , simple alterations in phosphodiesterase can not completely explain the cAMP data.
The second possible mechanism by which glucocorticoids might potentiate PTH-stimulated cAMP is by activation of the adenylate cyclase system. Stimulation of adenylate cyclase activity was found in OB cells but not OC cells (Fig. 3) . NaF-stimulatable cyclase activity was doubled in OB cells as was the enzyme response to all concentrations of PTH. These data suggest that glucocorticoids increased the endogenous enzyme activity. Although the basal activity of enzyme was not measurably increased by dexamethasone, changes in enzyme content may not be detectable at the low activity level of unstimulated enzyme.
The molecular mechanisms regulating adenylate cyclase activity are very complex (15, 16 (Table III) . Moreover, dexamethasone caused a further potentiation of enzyme activity than that caused by the addition of 10 ,uM Gpp(NH)p (Table III) The glucocorticoid action to potentiate PTHstimulated cAMP exhibited both an increase in sensitivity to PTH as well as the attainment of higher maximal levels of cAMP (Fig. 4) . The effect was qualitatively similar in both cell types although quantitatively different. Because inhibition of phosphodiesterase and stimulation of adenylate cyclase were found in OB cells, while only inhibition of phosphodiesterase was detected in OC cells, it is difficult to ascribe an action to the change in each enzyme. It is possible that we failed to detect a stimulation ofadenylate cyclase in a subpopulation of OC cells.
An additional mechanism which has to be considered is that glucocorticoid treatment induced the synthesis of additional PTH The present studies indicate that glucocorticoids exhibit two different types of action directly at the bone cell level. Both actions are seen in both OBand OC-cell types. The first action is a general inhibitory effect, which is also seen in many other tissues (23, 24) . The expectation is that this action would result in reduced bone formation as well as a reduced rate of bone resorption because of an inhibition of OB-and OC-cell proliferation and function. The second action is a potentiation of PTH-stimulated cAN1P production. PTH inhibits OB cell activity and decreases collagen formation (25, 26) . cAMP is considered the intracellular mediator of these effects (26) . Therefore, by potentiating PTH action, glucocorticoids maxv inhibit OB cells by a second pathway.
The direct inhibition of OC cells by glucocorticoids may possibly provide an explanation for the findings that glucocorticoids inhibit PTH-mediated bone resorption in organ culture after brief exposure to low doses of PTH (27) (28) (29) . However, cAMP is considered the likely second messenger for PTH-mediated bone resorption, although this remains controversial (27) . Thus, the steroid action to enhance PTH-stimulated cANIP may potentially increase bone resorption. Our findings of two glucocorticoid actions provides for a possible increase or decrease in OC cell activity. Which action prevails, either inhibition of OC cells directly or potentiation of PTH action, is probably determined by the relative concentrations of hormones as well as other still unknown factors.
In sumImary, this paper has described direct actions of glucocorticoids on rat bone cells in culture. The findings suggest that OB cells are inhibited both directly and by a potentiation of PTH action, whereas OC cells are directly inhibited but potentiation of PTH-stimulated cAMIP may lead, at least theoretically, to enhanced resorption. These consequences of glucocorticoid actions are consistent with current interpretations of bone morphology in patients exposed to excess corticosteroids (30) .
